Guidant gets OK to expand US DES (drug-eluting stent) trial:
This article was originally published in Clinica
Executive Summary
The FDA has given Guidant the green-light to expand enrolment in the US portion of its SPIRIT III drug-eluting stent (DES) trial to the full cohort of 1,292 patients at up to 80 sites. The study is comparing the firm's everolimus-eluting stent, XIENCE V, with the current market-leading DES, Boston Scientific's paclitaxel-eluting stent, Taxus. Results from SPIRIT III will be used to seek FDA approval for XIENCE V for treating coronary artery disease. Guidant initially received conditional investigational device exemption approval to begin the trial with a limited number of sites in May. Some 117 patients have been enrolled in the study to date. XIENCE V comprises as its stent platform Guidant's cobalt chromium Multi-Link Vision system.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.